Testing the Addition of an Investigational Scan (PSMA-PET) to Standard MRI Imaging for Diagnosing Residual or Recurrent Disease in Patients who Undergo Focal Therapy for Localized Prostate Cancer
This clinical trial evaluates whether adding prostate specific membrane antigen (PSMA)-positron emission tomography (PET) to standard multiparametric magnetic resonance imaging (mpMRI) is useful for diagnosing cancer that remains (residual) or has come back (recurrence) following standard focal therapy for prostate cancer that has not spread to other parts of the body (localized or non-metastatic). As part of clinical care, men with prostate cancer can choose to receive focal therapy (partial prostate ablation) to target and destroy prostate cancer cells without losing their entire prostate. While focal therapy can help treat prostate cancer, sometimes the therapy does not destroy all prostate cancer cells or the prostate cancer comes back after treatment, which is why men who have had focal therapy are often asked to return for magnetic resonance imaging (MRI) and routine prostate biopsies to check the status of their prostate cancer. MRI alone has been shown to miss cancer in some people and therefore routine biopsies are necessary after focal therapy. These standard monitoring biopsies can be painful, inconvenient and expensive to experience after focal therapy, which is why this study aims to see if combining imaging procedures (such as PSMA and mpMRI scans) can be used instead to effectively monitor/detect prostate cancer after focal therapy. An mpMRI scan is an imaging test that scans and takes detailed pictures of the prostate. Unlike regular MRIs, an mpMRI produces a more detailed image of the prostate. Similar to PET scans, mpMRI scans use an imaging dye that helps the pictures of the prostate appear clearer on scans. A PSMA PET scan is another type of imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate. Combining PSMA-PET with standard mpMRI may be a more effective way to monitor prostate cancer after focal therapy, and may help reduce the number of routine biopsies patients have to receive as part of standard monitoring after focal therapy.